OCRELIZUMAB AND HYALURONIDASE-OCSQ

Ocrelizumab And Hyaluronidase-ocsq Overview

Ocrelizumab and hyaluronidase-ocsq (brand name Ocrevus Zunovo) is a prescription medicine used to treat adults with relapsing or primary progressive forms of multiple sclerosis (MS). It offers the exact same active MS treatment as the original Ocrevus, but instead of a long intravenous (IV) infusion, it is given as a much faster injection just under the skin of the stomach.

Key Facts Summary:

What Is Ocrelizumab And Hyaluronidase-ocsq and How Does It Work?

This medication combines two different active ingredients to make the treatment both clinically effective and fast to administer.

Mechanism of Action

In multiple sclerosis, autoreactive immune cells mistakenly attack the protective myelin sheath surrounding nerve fibers in the central nervous system. Specific B cells expressing the CD20 cell-surface marker drive this inflammatory response.

• Ocrelizumab: This humanized monoclonal antibody binds directly to the CD20 cell-surface antigen on pre-B and mature B lymphocytes. Binding induces antibody-dependent cellular cytolysis and complement-mediated lysis, depleting circulating autoreactive CD20-positive B cells and preventing them from migrating into the central nervous system to cause neuroinflammation and tissue damage.
• Hyaluronidase-ocsq: The subcutaneous extracellular matrix contains hyaluronic acid, a polysaccharide that creates a physical barrier limiting the rate and volume of fluid absorption. Hyaluronidase-ocsq is an endoglycosidase that temporarily depolymerizes hyaluronic acid in the local subcutaneous space. This temporarily increases tissue permeability, allowing the large therapeutic volume of ocrelizumab to be injected subcutaneously in approximately 10 minutes and rapidly absorbed into systemic circulation.

Is Ocrelizumab And Hyaluronidase-ocsq FDA Approved?

Yes, the combination of ocrelizumab and hyaluronidase-ocsq is officially approved by the United States Food and Drug Administration.

What Is Ocrelizumab And Hyaluronidase-ocsq Used For?

• Relapsing forms of multiple sclerosis (RMS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
• Primary progressive multiple sclerosis (PPMS) in adults.

Before Taking Ocrelizumab And Hyaluronidase-ocsq: Contraindications and Precautions

Because this drug depletes B cells, your medical team will verify your immune status and screen for active viral infections prior to therapy.

Who Should Not Take Ocrelizumab And Hyaluronidase-ocsq?

• Anyone with an active Hepatitis B virus (HBV) infection.
• Anyone with a history of life-threatening hypersensitivity or severe systemic allergic reactions to ocrelizumab, hyaluronidase-ocsq, or any of the inactive ingredients.

Ocrelizumab And Hyaluronidase-ocsq, Pregnancy and Fertility

Discuss pregnancy plans with your doctor. Ocrelizumab crosses the placenta and can cause fetal B-cell depletion and lymphopenia in newborn infants. Females of reproductive potential should use effective contraception during treatment and for at least 6 months after the final injection. It is unknown if this medicine passes into human breast milk. Talk to your doctor about the best way to feed your baby.

Tell Your Doctor Before Taking Ocrelizumab And Hyaluronidase-ocsq

• Disclose any active infections or a history of frequent, recurrent, or hard-to-treat infections.
• Inform your provider if you have ever had Hepatitis B or are a carrier of the virus.
• Share if you have a history of inflammatory bowel disease, severe gastrointestinal issues, or immune-mediated colitis.
• Provide a list of all recent vaccines. Live-attenuated vaccines must be completed at least 4 weeks prior to treatment.

Ocrelizumab And Hyaluronidase-ocsq Dosage and Administration

This medicine is administered exclusively by a trained healthcare professional in a clinic or outpatient facility equipped to manage potential hypersensitivity events. It is never administered intravenously.

Standard Ocrelizumab And Hyaluronidase-ocsq Dosing

• Recommended Dose: 920 mg of ocrelizumab and 23,000 units of hyaluronidase-ocsq per single-dose vial.
• Maintenance Schedule: Administered as a single subcutaneous injection once every 6 months.

How Ocrelizumab And Hyaluronidase-ocsq Is Administered

• Pre-medications: Approximately 30 to 60 minutes prior to injection, administer 100 mg IV methylprednisolone (or equivalent corticosteroid) and an oral or IV antihistamine (e.g., diphenhydramine) to reduce the risk of injection reactions. An antipyretic (e.g., acetaminophen) may also be administered.
• The medicine is injected directly into the subcutaneous tissue of the abdomen over approximately 10 minutes.
• Patients must be observed for at least 1 hour post-injection following the initial dose, and for at least 15 minutes post-injection for subsequent doses.

Ocrelizumab And Hyaluronidase-ocsq Clinical Efficacy and Research

FDA approval was supported by data from the Phase 3 OCARINA II trial, which demonstrated non-inferiority of subcutaneous ocrelizumab and hyaluronidase-ocsq compared to intravenous ocrelizumab. Pharmacokinetic analysis confirmed equivalent systemic exposure (AUC) and peak blood concentrations. Clinical results demonstrated rapid, near-complete depletion of CD20-positive B cells within two weeks, maintaining a high level of disease control against clinical relapses and brain lesions on MRI, while reducing administration time to 10 minutes.

Ocrelizumab And Hyaluronidase-ocsq Side Effects and Safety Profile

While effective for disease modification, peripheral B-cell depletion and subcutaneous tissue manipulation carry specific risks.

Common Ocrelizumab And Hyaluronidase-ocsq Side Effects

• Injection site reactions (erythema, pain, pruritus, or swelling at the injection site).
• Upper respiratory tract infections (nasopharyngitis, sinusitis).
• Headache.
• Fever, chills, or fatigue following injection.
• Herpes virus infections (herpes simplex, herpes zoster/shingles).

Serious Ocrelizumab And Hyaluronidase-ocsq Adverse Events

• Systemic Hypersensitivity Reactions: Severe allergic reactions, bronchospasm, anaphylaxis, or hypotension during or following injection.
• Serious Infections: Severe viral, bacterial, or fungal infections due to B-cell depletion; reactivation of latent Hepatitis B virus leading to hepatic injury or failure.
• Progressive Multifocal Leukoencephalopathy (PML): Opportunistic John Cunningham (JC) virus brain infection causing severe neurological deficits.
• Immune-Mediated Colitis: Severe gastrointestinal inflammation presenting as persistent diarrhea, severe abdominal pain, or gastrointestinal hemorrhage.

Managing Ocrelizumab And Hyaluronidase-ocsq Side Effects

Pre-medicating prior to each injection significantly reduces systemic hypersensitivity. Local injection site reactions (redness and mild pain) are typically transient and resolve without intervention. If systemic symptoms such as bronchospasm, facial swelling, or severe dizziness occur during or after administration, notify medical personnel immediately. Evaluate persistent fevers, chills, or respiratory symptoms promptly for underlying infection.

Ocrelizumab And Hyaluronidase-ocsq Drug Interactions and What to Avoid

Combining this targeted therapy with other immunomodulatory agents or administering live vaccines requires careful clinical coordination.

Ocrelizumab And Hyaluronidase-ocsq Drug-Drug Interactions

• Immunosuppressive Medications (Corticosteroids, DMARDs, biological agents): Concomitant use increases the risk of additive immunosuppression and severe systemic infections.
• Live Vaccines (e.g., MMR, Varicella, Yellow Fever): Live-attenuated vaccines are contraindicated during treatment and until B-cell repletion occurs due to the risk of vaccine-derived infection. Non-live vaccines should be administered at least 2 weeks prior to initiating therapy.

Ocrelizumab And Hyaluronidase-ocsq, Food and Alcohol

• Food intake does not affect subcutaneous absorption.
• Maintain normal hydration on injection days; avoid excess alcohol to support general immune health.

Ocrelizumab And Hyaluronidase-ocsq Missed Dose, Overdose and Storage

Consistent bi-annual administration maintains sustained B-cell suppression and prevents disease reactivation.

Missed Dose of Ocrelizumab And Hyaluronidase-ocsq

If a scheduled 6-month injection is delayed or missed, administer the dose as soon as possible. Do not wait until the next planned dose date. Reset the subsequent 6-month dosing schedule relative to the date of the newly administered dose.

Ocrelizumab And Hyaluronidase-ocsq Overdose and Emergency

Because this medication is prepared and administered solely by trained healthcare professionals, accidental overdose is unlikely. In case of dosing discrepancy, monitor the patient for exaggerated B-cell depletion and systemic toxicity.

How to Store Ocrelizumab And Hyaluronidase-ocsq

• Vials must be stored refrigerated between 36°F and 46°F (2°C and 8°C) in the original carton to protect from light.
• Do not freeze or shake.

Ocrelizumab And Hyaluronidase-ocsq Patient Management and Monitoring

Pre-treatment screening and ongoing laboratory evaluation ensure patient safety throughout long-term therapy.

Tests Before Starting Ocrelizumab And Hyaluronidase-ocsq

• Hepatitis B virus screening (HBsAg and total anti-HBc testing).
• Baseline serum immunoglobulin levels (IgG, IgA, IgM).
• Assessment of immunization status and completion of non-live vaccines at least 2 weeks prior.

Monitoring During Ocrelizumab And Hyaluronidase-ocsq Treatment

• Post-injection observation for hypersensitivity (1 hour for first dose, 15 minutes for subsequent doses).
• Screening for signs and symptoms of active infection prior to each injection.
• Periodic serum immunoglobulin testing (IgG, IgA, IgM).
• Monitoring for neurological signs indicative of PML or gastrointestinal signs indicative of immune-mediated colitis.

Ocrelizumab And Hyaluronidase-ocsq Do’s and Don’ts

• DO complete all baseline blood tests for Hepatitis B and immunoglobulins prior to treatment.
• DO report fever, chills, persistent cough, or localized pain to your physician immediately.
• DON’T rub or aggressively massage the abdominal injection site following administration.
• DON’T receive live-attenuated vaccines during therapy or prior to B-cell recovery.

Frequently Asked Questions

References

• U.S. FDA prescribing information for Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) injection
• U.S. FDA Drugs@FDA drug approval overview (Application No. 761371)
• OCARINA II Phase 3 Clinical Trial Results in Multiple Sclerosis

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider at any hospital or any local clinic before starting or stopping any medication.